TABLE 1.
Correlation between CBX3 expression and clinicopathologic characteristics of LUAD patients (n = 535).
| Characteristic | Low expression of CBX3 | High expression of CBX3 | p |
|---|---|---|---|
| n | 267 | 268 | |
| T stage, n (%) | 0.032 | ||
| T1 | 100 (18.8%) | 75 (14.1%) | |
| T2 | 132 (24.8%) | 157 (29.5%) | |
| T3 | 27 (5.1%) | 22 (4.1%) | |
| T4 | 6 (1.1%) | 13 (2.4%) | |
| N stage, n (%) | 0.013 | ||
| N0 | 187 (36%) | 161 (31%) | |
| N1 | 43 (8.3%) | 52 (10%) | |
| N2 | 27 (5.2%) | 47 (9.1%) | |
| N3 | 0 (0%) | 2 (0.4%) | |
| M stage, n (%) | 0.343 | ||
| M0 | 173 (44.8%) | 188 (48.7%) | |
| M1 | 9 (2.3%) | 16 (4.1%) | |
| Pathologic stage, n (%) | 0.205 | ||
| Stage I | 154 (29.2%) | 140 (26.6%) | |
| Stage II | 64 (12.1%) | 59 (11.2%) | |
| Stage III | 35 (6.6%) | 49 (9.3%) | |
| Stage IV | 10 (1.9%) | 16 (3%) | |
| Gender, n (%) | 0.631 | ||
| Female | 146 (27.3%) | 140 (26.2%) | |
| Male | 121 (22.6%) | 128 (23.9%) | |
| Smoker, n (%) | 0.422 | ||
| No | 41 (7.9%) | 34 (6.5%) | |
| Yes | 218 (41.8%) | 228 (43.8%) | |
| Age, n (%) | 0.034 | ||
| ≤65 | 114 (22.1%) | 141 (27.3%) | |
| >65 | 142 (27.5%) | 119 (23.1%) | |
| Age, meidan (IQR) | 67 (59, 74) | 65 (59, 71.25) | 0.011 |